Esomeprazole
- Generic Name
- Esomeprazole
- Brand Names
- Nexium, Vimovo, Nexium Control
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3O3S
- CAS Number
- 119141-88-7
- Unique Ingredient Identifier
- N3PA6559FT
- Background
Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison ...
- Indication
Esomeprazole is indicated for the treatment of acid-reflux disorders including healing and maintenance of erosive esophagitis, and symptomatic gastroesophageal reflux disease (GERD), peptic ulcer disease, H. pylori eradication, prevention of gastrointestinal bleeds with NSAID use, and for the long-term treatment of pathological hypersecretory conditions incl...
- Associated Conditions
- Duodenal Ulcer, Erosive Esophagitis, Gastro-esophageal Reflux Disease (GERD), Heartburn, Helicobacter Pylori Infection, Stress Ulcers, Upper Gastrointestinal Hemorrhage, Zollinger-Ellison Syndrome, Acute benign gastric ulcers, Develop NSAID-induced gastric ulcers, Maintenance of healing Erosive esophagitis, Postendoscopy Bleeding
- Associated Therapies
- -
A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued
- Conditions
- Interventions
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT00633672
Reflux Esophagitis Phase III Study (Initial Treatment)
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2010-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 602
- Registration Number
- NCT00633932
- Locations
- 🇯🇵
Research Site, Tottori, Japan
Reflux Esophagitis Phase III Study (Maintenance Treatment)
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2010-06-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 540
- Registration Number
- NCT00634114
- Locations
- 🇯🇵
Research Site, Tottori, Japan
Prevention of Gastric Ulcers
- Conditions
- Interventions
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2009-03-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 504
- Registration Number
- NCT00629512
An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT00629564
Ulcer Prevention II
- Conditions
- Interventions
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 800
- Registration Number
- NCT00629928
Adult Asthmatics and Acid Reflux
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2009-03-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1400
- Registration Number
- NCT00628953
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD)
- Conditions
- Interventions
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT00628342
Chronic Posterior Laryngitis With Suspected Laryngopharyngeal Reflux
- Conditions
- Interventions
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT00628667
A Multicenter, Randomized, Double-Blind Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg Once Daily to Placebo qd for the Resolution of Upper Abdominal Pain in Patients With Symptomatic Gastroesophageal Reflux Disease (sGERD)
- Conditions
- Interventions
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT00626535
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.